Change the Shape of your Clinical Development
Together, enhancing research with patient- and science-driven insight
Over 50 Years of Unparalleled Client Service
Building on a foundation of innovation and science, the lineage of Cerba Research is reflected in the breadth of our services. That includes expanded central lab, biomarker, IVD, and CDx offerings, as well as support from research and development through clinical studies and commercialization of therapies.
Our intent is to change the way drug development is achieved with our combined translational biomarker offerings. Our passion, expertise, and commitment to quality drive Cerba Research to become the new standard for changing the shape of your clinical development, and for helping patients around the world get access to new treatments faster.
Leverage patient data and scientific insight to shape and advance clinical trials by providing customized laboratory solutions to support global biotech, pharma, IVD, and research organizations to improve the lives of patients around the world.
Change the paradigm of clinical trial conduct and enable the acceleration of novel therapies by delivering scientific insights and leveraging vast patient data.
We act with the utmost rigor to improve the quality of our
services. We look for the best in our people, and their
ideas to continuously improve.
We promote entrepreneurial spirit and embrace those who
take initiatives to dare to explore new ways to Advance
Research, Advance Health
We are committed to drug development and research that
delivers insightful, accurate data that improves health.
We consider each individual with kindness, and cultivate
respect in our relationships with our teams, partners,
healthcare professionals and patients for whom we work
Since 1983, Cerba Research has been synonymous with innovation, and our identity is indivisible from our tireless pursuit of the breakthroughs that change patient lives.
Cerba Research’s strength is born of its flexibility and courage; as the needs of patients, clients, and employees change, we can only be as agile as we are courageous.
Every conversation at Cerba research begins with a commitment to transparency, excellence and honesty, ensuring actions based on integrity and quality follow.
Cerba Research hires the best employees specifically so we can empower them to fulfill their full potential — this growth is the engine that drives the company forward.
The patient is at the heart of everything Cerba Research does and is our nonnegotiable first priority.
The Cerba Research legacy began in 1967 with the establishment of Laboratoire CERBA, a leading European laboratory in specialized biology. The timeline below shows how Cerba Research has evolved since, through organic growth and partnerships.
2021 CERBACT ASIA, IMMUNO-ONCOLOGY CENTER OF EXCELLENCE
In August, Cerba Research and ACT Genomics joined to create a purpose-built lab facility in Taiwan to support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
2021 BIOKORTEX PARTNERSHIP
Cerba partners with Biokortex, a provider of digital solutions to the healthcare sector. The partnership allows us to provide our customers with patient identification and recruitment solutions by leveraging patient biological and medical data.
2020 HISTALIM, CERBA XPERT & BARC LAB BECOME CERBA RESEARCH
We kicked off 2020 strongly by launching Cerba Research, weaving three of the Cerba Healthcare companies into one to provide better solutions to our clients and to the patients they serve. Learn More
2019 OWL METABOLOMICS PARTNERSHIP
Cerba partners with Vizcaya, Spain’s OWL Metabolomics, providing our customers with solutions to develop tailored treatments for NASH patients.
2019 PPC (TAIWAN) PARTNERSHIP
Cerba partners with clinical and laboratory services provider PPC Taiwan, further expanding its Asian footprint.
2018 BARC BECOMES BARC LAB
At the end of a year marked by growth and change, BARC becomes Barc Lab.
2018 CERBA HEALTHCARE/LANCET AFRICA JOINT VENTURE
Cerba Healthcare and Lancet Laboratories launch a joint venture, Cerba Lancet Africa, combining the strength and knowledge of our leading European laboratories with Lancet’s specialized labs throughout Africa.
2018 TEDDY LAB PARTNERSHIP (CHINA)
Cerba partners with Shanghai, China’s Teddy Lab, allowing us to offer our clients a wider range of testing in China.
2018 ACQUISITION OF HISTALIM
Cerba broadens its expertise once more by acquiring HISTALIM, a histopathology and immunohistochemistry specialty lab in 2005 in Montpellier, France.
2015 CERBA LAB TO CERBA HEALTHCARE
Having grown to encompass medical laboratories and a global central lab fostering clinical trials all over the world, it was time for a name change. Cerba Lab becomes Cerba Healthcare.
2012 BARC CHINA FOUNDED
The founding of BARC’s China office expands our global footprint.
2012 Cerba Xpert Founded
Cerba Xpert, provider of tailor-made solutions to evaluate IVD devices and developer of quality control solutions, was created in 2012.
2009 SRL MEDISEARCH PARTNERSHIP
Cerba partners with Tokyo, Japan’s SRL Medisearch to better support clinical trials on a global scale.
For over 50 years, Cerba Research has evolved in one direction: toward better serving our customers. From corporate acquisitions to international expansions to everyday decision-making, one question guides our approach: Will this help us to better serve our customers?
The unsurpassed innovation of our combined translational biomarker offerings, combined with the full resources of our expert scientists, achieve their maximum potential only through a true partnership with you. We understand that to your customers, our performance is your performance — and that your reputation is on the line with every deadline and each deliverable.
It is within our grasp, today, to usher in the next generation of protocol conduct. As your partner, Cerba Research empowers you to bring new, life-changing therapies to patients worldwide.
We can change the shape of your clinical development. Together, enhancing research with patient- and science-driven insight.